Dutalys Overview

  • Founded
  • 2010
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $489M
Latest Deal Amount

Dutalys General Information


Developer of human, bi-specific antibodies used in drugs. The company specializes in the discovery and development of bi-specific and monoclonal antibodies used in pharmaceutical and therapeutic drugs.

Contact Information

Ownership Status
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Muthgasse 11/2
  • Vienna, 1190
  • Austria
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Dutalys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 18-Dec-2014 $489M 00000 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Dutalys’s complete valuation and funding history, request access »

Dutalys Executive Team (2)

Name Title Board Seat Contact Info
Roland Beckmann Ph.D Chief Scientific Officer and Co-Founder
You’re viewing 1 of 2 executive team members. Get the full list »

Dutalys Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
INiTS Universitäres Gründerservice Accelerator/Incubator 000 0000 000000 0
To view Dutalys’s complete investors history, request access »